We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+13.18%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$25B
AUM Growth
+$2.35B
Cap. Flow
+$638M
Cap. Flow %
2.55%
Top 10 Hldgs %
85.68%
Holding
126
New
11
Increased
17
Reduced
63
Closed
6

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$358M
2
PRLD icon
Prelude Therapeutics
PRLD
+$286M
3
KYMR icon
Kymera Therapeutics
KYMR
+$59.8M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$55.5M
5
NRIX icon
Nurix Therapeutics
NRIX
+$45.1M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$94.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$26.6M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$21.6M
4
INSM icon
Insmed
INSM
+$21.6M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.7%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADPT icon
51
Adaptive Biotechnologies
ADPT
$4.15B
$21.4M 0.09%
440,539
-23,000
-5% -$967K
NVAX icon
52
Novavax
NVAX
$1.47B
$20.3M 0.08%
187,376
-54,000
-22% -$6.58M
IMMU
53
DELISTED
Immunomedics Inc
IMMU
$20.2M 0.08%
237,694
-92,306
-28% -$4.67M
ALBO
54
DELISTED
Albireo Pharma Inc
ALBO
$18.3M 0.07%
549,047
+180,000
+49% +$5.24M
KRRO icon
55
Korro Bio
KRRO
$194M
$18.2M 0.07%
18,991
+77
+0.4% +$82.7K
LONA
56
LeonaBio Inc
LONA
$72.4M
$16.3M 0.07%
+88,235
New +$14.7M
XNCR icon
57
Xencor
XNCR
$2.07B
$15.9M 0.06%
410,142
-17,978
-4% -$625K
BLUE
58
DELISTED
bluebird bio
BLUE
$13.6M 0.05%
19,454
-1,004
-5% -$783K
HRMY icon
59
Harmony Biosciences
HRMY
$2.22B
$13.6M 0.05%
+400,000
New +$14.6M
GWPH
60
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$13.5M 0.05%
138,745
-46,300
-25% -$5.33M
MIRM icon
61
Mirum Pharmaceuticals
MIRM
$5.87B
$10.7M 0.04%
553,009
-30,324
-5% -$651K
IMTX icon
62
Immatics
IMTX
$1.22B
$10.6M 0.04%
1,001,414
+851,414
+568% +$8.97M
VXRT
63
DELISTED
Vaxart
VXRT
$10.4M 0.04%
1,566,121
-73,000
-4% -$650K
ACGN
64
DELISTED
Aceragen Inc
ACGN
$9.86M 0.04%
271,376
– –
UROV
65
DELISTED
Urovant Sciences Ltd.
UROV
$9.14M 0.04%
978,505
-21,495
-2% -$191K
SGMO
66
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$8.98M 0.04%
949,823
-50,000
-5% -$541K
XENE icon
67
Xenon Pharmaceuticals
XENE
$5.88B
$8.42M 0.03%
760,308
-38,794
-5% -$456K
ISEE
68
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$7.93M 0.03%
1,406,037
-229,464
-14% -$1.09M
ANAB icon
69
AnaptysBio
ANAB
$1.71B
$7.19M 0.03%
487,243
-26,434
-5% -$477K
QURE icon
70
uniQure
QURE
$3.36B
$7.16M 0.03%
194,383
-36,500
-16% -$1.5M
CABA icon
71
Cabaletta Bio
CABA
$531M
$6.9M 0.03%
636,363
– –
HOOK
72
DELISTED
HOOKIPA Pharma
HOOK
$6.63M 0.03%
70,048
– –
SYRS
73
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$6.1M 0.02%
69,017
– –
KRTX
74
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$6.01M 0.02%
77,776
-4,200
-5% -$358K
BNR
75
Burning Rock Biotech
BNR
$103M
$5.95M 0.02%
23,730
-1,270
-5% -$301K
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2020 Portfolio in Review

As of Q3 2020, Julian Baker held 126 positions worth $25B, up 10% from $22.7B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q3 2020 filing shows 11 new, 17 increased, 63 reduced and 6 closed positions. Its largest new stake was Prelude Therapeutics: 10,118,636 shares worth $305M. The largest sale was Principia Biopharma Inc. Common Stock, an estimated $94.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q3 2020 buy was Prelude Therapeutics: 10,118,636 shares worth $305M.
  • Julian Baker added most to BeOne Medicines Ltd in Q3 2020, an estimated $358M increase.
  • Julian Baker's biggest Q3 2020 reduction was Neurocrine Biosciences, cutting an estimated $26.6M.
  • Julian Baker fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $94.5M.
  • Julian Baker's ten largest holdings make up 86% of its $25B portfolio in Q3 2020.
  • Julian Baker opened 11 new positions and closed 6 in Q3 2020.
  • Julian Baker's portfolio value rose 10% quarter-over-quarter to $25B.

Based on Baker Bros. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.